申请人:Matsumoto Yoshiyuki
公开号:US20070037851A1
公开(公告)日:2007-02-15
The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C
1
-C
6
alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.
本发明提供了具有抑制CCR3配体与靶细胞上CCR3结合活性的低分子化合物,即CCR3拮抗剂。本发明还提供了由下式(I)所表示的4,4-(二取代)哌啶衍生物,其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物,以及包含它们作为有效成分的药物组合物,用于治疗或预防与CCR3相关的疾病,如哮喘和过敏性鼻炎。